U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered ...

Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...

Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...

Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...

Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Meanwhile, Clorox, considered a recession-proof stock, has recently declined as the market rebounded, making it a potential gauge for the continuation of the bull market phase. Marriott's earnings ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...

Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Novo ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...